Author:
Palmieri C,Gojis O,Rudraraju B,Stamp-Vincent C,Wilson D,Langdon S,Gourley C,Faratian D
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Ueno W, Wampler GL, Yeung KY, Alt D (1993) Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 10: 1957–1968
2. Alkner S, Bendahl PO, Grabau D, Lövgren K, Stål O, Rydén L, Fernö M Swedish and South-East Swedish Breast Cancer Groups (2010) AIB1 is a predictive factor for tamoxifen response in premenopausal women. Ann Oncol 21: 238–244
3. Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of using ‘optimal’ cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829–835
4. Bai J, Uehara Y, Montell DJ (2000) Regulation of invasive cell behavior by taiman, a Drosophila protein related to AIB1, a steroid receptor coactivator amplified in breast cancer. Cell 103: 1047–1058
5. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, Smyth JF (2002) CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 8: 2233–2239
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献